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Abstract
Background: Despite the burden of progressive incurable disease in Africa, there is almost no evidence on patient
care or outcomes. A primary reason has been the lack of appropriate locally-validated outcome tools. This study
aimed to validate a multidimensional scale (the APCA African Palliative Outcome Scale) in a multi-centred
international study.
Methods: Validation was conducted across 5 African services and in 3 phases: Phase 1. Face validity: content
analysis of qualitative interviews and cognitive interviewing of POS; Phase 2. Construct validity: correlation of POS
with Missoula-Vitas Quality of Life Index (Spearman’s rank tests); Phase 3. Internal consistency (Cronbach’s alpha
calculated twice using 2 datasets), test-retest reliability (intraclass correlation coefficients calculated for 2 time
points) and time to complete (calculated twice using 2 datasets).
Results: The validation involved 682 patients and 437 family carers, interviewed in 8 different languages. Phase 1.
Qualitative interviews (N = 90 patients; N = 38 carers) showed POS items mapped well onto identified needs;
cognitive interviews (N = 73 patients; N = 29 carers) demonstrated good interpretation; Phase 2. POS-MVQoLI
Spearman’s rank correlations were low-moderate as expected (N = 285); Phase 3. (N = 307, 2nd assessment mean
21.2 hours after first, SD 7.2) Cronbach’s Alpha was 0.6 on both datasets, indicating expected moderate internal
consistency; test-retest found high intra-class correlation coefficients for all items (0.78-0.89); median time to
complete 7 mins, reducing to 5 mins at second visit.
Conclusions: The APCA African POS has sound psychometric properties, is well comprehended and brief to use.
Application of this tool offers the opportunity to at last address the omissions of palliative care research in Africa.
Background
The lack of clinical and research activity to enhance care
of the dying among those HIV-infected is a global chal-
lenge. Despite two million deaths during 2007, with
emerging international data reporting high mortality
even as access to therapy increases, very little scientific
attention is paid to improving the experience of death
and dying [1].
The burden of progressive, life-limiting disease in Sub-
Saharan Africa is reflected in the epidemiology of HIV
[2,3] and cancer [4]. In sub-Saharan Africa during 2007
there were 22.5 million people living with HIV infection;
1.7 million adults and children became infected with
HIV; and 1.6 million died of AIDS [1]. Based on GLO-
BOCAN 2002 cancer rates and UN population predic-
tions, there were an estimated 7.6 million new cancer
cases and 6 million deaths from cancer in Africa in
2007 [5], and malignancies are a common presentation
of HIV progression. The burden of other progressive
non-malignant diseases is unknown.
Significant advances have been achieved in African
palliative care provision to manage the highly prevalent
and burdensome problems experienced by those with
incurable terminal disease. However, there is very little
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common problem in developing country contexts, where
health systems research is under-funded [6,7]. A primary
reason for this dearth of evidence is the lack of appro-
priate and validated outcome tools [8], among other
logistical and methodological challenges in this setting
and population [9].
Advanced care clinicians in Africa identified the need
for appropriate outcome tools [10], and suggested that
these tools should be appropriate for both HIV and can-
cer patients, address family and patient outcomes, be
locally validated [11], and be relevant to all stages of the
disease trajectory [12]. In addition to validity and relia-
bility, key principles of outcome tools are brevity and
multidimensionality, i.e. addressing physical, emotional,
spiritual and social problems of both patients and
families. Self-completion tools are often inappropriate
for patients with advanced illness, and may not be feasi-
ble in populations with limited literacy.
To date, only one palliative measure has been vali-
dated in Africa [13]. The Missoula Vitas Quality of Life
Index (MVQoLI) is a 25-item measure developed in the
USA and validated in Uganda. However, the tool was
originally designed for use in clinical care, and was not
studied comprehensively as an outcome measure. Psy-
chometric testing of a revised version of the tool con-
cluded that it does not have appropriate properties for
outcomes research in patients with advanced illness
[14].
The original Palliative Outcome Scale (POS) is a 10-
item multidimensional tool [15], adapted and validated
globally in a number of cultural and linguistic versions
[16-18]. Independent assessments of the utility of the
POS have identified it as useful and valid in clinical
audit, training and research [19,20]. This study reports
the validation (i.e. investigation of the degree to which
the instrument accurately and reliably measures what it
intends to) of the APCA African POS, a tool developed
by a multi-professional expert panel and piloted in 11
sites in 8 Eastern and Southern African countries (Bots-
wana, Kenya, Malawi, South Africa, Tanzania, Uganda,
Zambia and Zimbabwe). The developmental pre-clinical
phase has been reported previously (i.e. content and
consensus validity) [21], and tested whether the measure
could: (a) yield information of clinical relevance to pal-
liative care, (b) cover those domains considered to be
important to this type of care and nothing more, and (c)
achieve a consensus among specialists that (a) and (b)
had been met. Subsequent consultation was undertaken
with a panel of African clinicians [11]. During this
developmental phase, sensitivity to change was also
reported on the original pool of potential items.
In this paper we report the full, international, multi-
centre clinical validation of the tool.
Methods
This validation study used a 3-phase clinical study
design: Phase 1 Face validity; Phase 2 Construct validity;
Phase 3 Internal consistency, test/re-test reliability and
time to complete (Figure 1).
Participating Sites
The validation was undertaken in 5 palliative care sites,
4 in South Africa and 1 in Uganda, based in rural, peri-
urban and urban areas, including homecare, day care
and inpatient facilities. Two of the sites provide care
from the point of diagnosis through to the end of life
while the remaining 3 focus primarily on advanced
disease.
PHASE 2:  
Construct Validity 
Cross sectional POS & 
MVQoL correlation 
Patients n=285 
 Families  n=199 
PHASE 3: 
a) Internal consistency 
b) Test-retest reliability 
c) Time to complete  
 Patients  n=307 
 Families  n=200 
PHASE 1: Face Validity 
a) Qualitative 
interviews mapping 
expressed needs to 
tool items 
Patients n=90 
Families n=38 
b) Cognitive  interviews 
to investigate 
comprehension 
Patients n=73 
Families n=29
Figure 1 Study Design.
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Inclusion criteria were adult patients (at least 18 years
old) under care with sufficient physical and cognitive
ability to participate in interviews. All information and
consent forms and tools were translated from English
(forward and back) into the principle languages of
Luganda, Runyankole, Sesotho, Runyoro, SeTswana,
isiXhosa and 2 isiZulu dialects. Informed consent was
obtained from all participants. The study was reviewed
and approved by the Ethical Review Boards of the Uni-
versities of Cape Town, KwaZulu Natal and Witwaters-
rand, the Ugandan National Council for Science and
Technology, Hospice Africa Uganda and the Hospice
Palliative Care Association of South Africa.
The APCA African POS
The APCA African POS contains 10 items, addressing
the physical and psychological symptoms, spiritual, prac-
tical and emotional concerns, and psychosocial needs of
t h ep a t i e n ta n df a m i l y( s e eA d d i t i o n a lF i l e1 ) .T h e
answers to all questions are scored using Likert scales
from 0 to 5, with numerical and descriptive labels.
Questions 1-7 are directed at patients; questions 8-10
are directed at family informal caregivers and include a
‘Not applicable’ option for use when the patient does
not have an informal carer. The African version of the
POS is staff-completed, owing to varying levels of
patient and family literacy. Respondents indicate their
answers either verbally or using a hand scale (0 = closed
fist, 5 = all fingers open). The responses use a combina-
tion of high score = best status and low score = best
status as a mechanism to ensure that administration,
and response formulation to the individual items, are
conducted with due care and attention. The tool used
throughout this validation study was not changed from
the original development study.
Validity and Reliability
The measure was tested by evaluating the components
of validity and reliability described below. Trained pal-
liative care research nurses (TM, KM, GA and two
others) and three assistants administered all testing
procedures.
i. Face validity: patients’ and carers’ views (Phases 1a and
1b)
Face validity relates to the appropriateness and accept-
ability of the measure to the target population. In-
depth qualitative interviews with patients and carers
were conducted in order to ensure that domains of
need mapped on to POS items (Phase 1a). Cognitive
interviews were conducted to explore whether the
respondents found any questions confusing, upsetting,
or irrelevant, to understand perceived meaning, to
determine how they formulated responses, and identify
whether any important issues were felt to be missing
(Phase 1b) [22].
ii. Construct validity (Phase 2)
Assessing construct validity ideally involves comparing a
measure with a different measure of the same construct
that has previously been validated in the same popula-
tion, in order to determine convergence or divergence.
The only palliative care scale previously validated in a
similar population was the MVQoLI [13]. The original
MVQoLI is a measure of quality of life during advanced
illness. Its distinctive features are a scoring system that
allows the weighting of each dimension of QOL by the
respondent, and the subjective wording of the items that
allows respondents to interpret the measured elements
according to their own experience [23]. Patients com-
pleted both the POS and MVQoLI at a single time
point. POS carer items (8-10) were completed by family
carers where available. The MVQoLI is divided into 5
subscales: symptoms, function, well being, interpersonal
and transcendent. There are important differences
between the two measures. The MVQoLI is considerably
longer than the POS (26 items compared to 10), the
MVQoLI does not measure family carers’ well being,
and the MVQoLI addresses physical function. Owing to
these differences, it was hypothesised that a high degree
of correlation would not be found (i.e. that correlation
would be less than 0.6).
iii. Internal consistency (Phase 3)
Testing for internal consistency involves estimating how
consistently individuals respond to the items within a
scale. Where items within a scale measure different ele-
ments of patient experience (as in this multidimensional
tool) a moderate Cronbach’s alpha (i.e. approximately
0.5), rather than a high alpha (i.e. >0.7), is expected.
iv. Test/re-test reliability (Phase 3)
Test/retest reliability measures the stability of a measure
over a short time period, i.e. determines whether a mea-
sure is sensitive to change but not so sensitive as to
report clinically insignificant changes. Test/re-test relia-
bility was measured on two consecutive visits within 5-
48 hours.
v. Time to complete (Phase 3)
Time taken to complete a measure is important when
assessing appropriateness for a patient group and use in
clinical practice, particularly in populations living with
advanced illness. Research nurses timed the administra-
tion of the POS during the test/re-test reliability phase
t og a u g et i m et oc o m p l e t et h et o o lu n d e rt y p i c a l
repeated use. During Phase 2, time to complete the
MVQoLI was also recorded for comparison purposes.
Demographic data
For each phase of the validation, the following patient
demographic and clinical data were collected: age, gen-
der, first language, language of interview, diagnosis (for
cancer patients, also cancer type; for HIV patients, also
antiretroviral (ART) treatment status, prior AIDS
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ble for, location of home (urban, peri-urban, rural), pri-
mary place of care (home, inpatient/outpatient unit, day
care facility), functional status (using the ECOG [24]),
and time under care in weeks. In the qualitative phase
of validation family carers reported age, gender, first lan-
guage, language of interview, household size, number of
children responsible for, and location of home (urban,
peri-urban, rural).
We elected to collect data on the number of children
that respondents were responsible for, rather than num-
ber of biological children. This was because within
Africa multiple AIDS deaths within the same family,
and broader concepts of what constitutes “family”, mean
adults may care for children other than their own, e.g.
grandchildren, nephews and nieces.
Translation and data capture
The APCA African POS, MVQoLI, qualitative inter-
view schedule, demographic record, and information
and consent sheets were translated from English into
the main local languages (isiXhosa, isiZulu (Gauteng
and KwaZulu Natal dialects), SeSotho, SeTswana,
Luganda and Runyoro). The translations were underta-
ken in Academic departments hosting the research and
were therefore professional in their skills and knowl-
edge of both language and topic. The research nurses
entered quantitative data into purpose-designed Excel
spreadsheets, subsequently imported into SPSS for ana-
lysis. Qualitative and cognitive interviews were con-
ducted in local languages and digitally recorded. The
project research nurses and their assistants transcribed
qualitative and cognitive interviews verbatim and
translated the transcripts into English. Translations
were peer reviewed by local service colleagues fluent in
both English and the relevant local language to check
accuracy of translations.
Role of the funding source: The study sponsor (the
BIG Lottery Fund UK) had no role in study design; the
collection, analysis and interpretation of data; the writ-
ing of the report; or the decision to submit the paper
for publication.
Analysis
i. Face validity: patients’ views (Phases 1a and 1b)
A thematic content analysis of translated transcripts was
conducted following import into NVivo v7. The
domains of the POS were mapped on to the qualitative
interview themes with respect to patient and carer
needs, and goodness of fit appraised. Each item was
reviewed for appropriateness in light of cognitive inter-
view data, and any training needs to ensure comprehen-
sion were noted. Data was presented to the entire
project team for discussion and feedback at key points
during the analysis process.
ii. Construct validity (Phase 2)
POS scores were transformed so that for all items high
scores indicated better patient status (i.e. scoring for
items 1, 2, 3 and 10 were reversed), in line with
MVQoLI scoring. Analyses were undertaken using the
weighted subscales, as used in the original validation of
the MVQoLI. Before running the correlation data were
cleaned, screened for any outliers and distributions of
scores checked for normality. Spearman’sr a n kw a s
selected for the correlation analyses as a conservative
non-parametric test. Spearman’s rank test was used to
correlate the POS against the MVQoLI in the following
ways: POS total/MVQoLI total score, and POS total for
patient items only (1-7)/MVQoLI total score. The
MVQoLI symptom subscale was correlated against the
sum of POS items 1 (pain) and 2 (symptoms). The
MVQoLI interpersonal subscale was correlated against
POS item 4 (ability to share feelings). The MVQoLI well
being subscale was correlated against the sum of POS
items 3 (patient worry), 6 (feeling at peace) and 7 (help
and advice). The MVQoLI transcendence subscale was
correlated against POS item 5 (life feeling worthwhile).
Decisions regarding which POS items to correlate with
the MVQoLI subscales were made on the basis of best
fit between items in the respective tools.
iii. Internal consistency (Phase 3)
Cronbach’s alpha was calculated twice, using two data-
sets from the same sample, collected during assessment
of test/re-test reliability.
Test/re-test reliability (Phase 3)
Intraclass correlation coefficients (ICC) were calculated
for two time points.
v. Time to complete (Phase 3)
Median and mean times to complete were calculated
from the two POS administrations during the test/re-
test reliability phase. Mean, median and ranges of time
to complete were also calculated for the MVQoLI, for
purposes of comparison.
A level of p < 0.05 (two-tailed) was selected for all
tests of significance.
Results
Participant characteristics
Validation of the APCA African POS involved inter-
views with a total of 682 patients and 437 family carers.
Respondent characteristics for each validation phase are
shown in Table 1. Across the phases of validation,
respondents reported 28 different first languages and
interviews were conducted in 8 different languages
(49.6% IsiZulu, 15.3% English, 12.8% isiXhosa, 6.4%
Luganda, 6.3% SeSotho, 5.4% Runyoro, 3.9% Runyankole
and 0.4% SeTswana) (N = 720; language data not col-
lected for remaining 399 carers).
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Phase 1a
(ii) Face validity: qualitative
interview
Phase 1b
(ii) Face validity: cognitive
interview
Phase 2
(iii) Construct
validity
Phase 3
(iv) Internal
consistency,
(v) Test-retest
reliability &
(vii) Time to complete
PATIENTS N 90 73^ 285 307
Age
Mean (SD) 43.2 (15.4) 44.8 (16.0) 40.1 (12.8) 41.9 (14.1)
Gender
Female 58 (64.4%) 49 (67.1%) 197 (69.1%) 207 (67.4%)
Primary diagnosis
Cancer 34 (37.8%) 33 (45.2%) 86 (30.2%) 90 (29.3%)
HIV 61 (67.8%) 44 (60.3%) 229 (80.4%) 244 (79.5%)
Of HIV+ pts:
On ART 39 (63.9%) 24 (54.5%) 127 (55.5%)
a 140 (57.4%)
Prior AIDS
diagnosis 54 (88.5%) 37 (84.1%) 192 (83.8%) 196 (80.3%)
ECOG Functional
status
Fully active 10 (11.1%) 8 (11.0%) 21 (7.4%) 29 (9.4%)
Restricted 24 (26.7%) 24 (32.9%) 65 (22.8%) 79 (25.7%)
Ambulatory 17 (18.9%) 17 (23.3%) 79 (27.7%) 71 (23.1%)
Limited self care 25 (27.8%) 14 (19.2%) 87 (30.5%) 101 (32.9%)
Completely disabled 14 (15.6%) 10 (13.7%) 33 (11.6%) 27 (8.8%)
Household size
Mean (SD) 5.2 (5.0)
a 4.9 (3.1)
a 5.3 (2.5)
b 5.5 (3.2)
Responsible for
children?
Yes 68 (75.6%) 54 (74.0%) 232 (81.4%) 238 (77.5%)
Mean no. of children
(SD)
2.8 (1.8) 2.9 (1.8) 3.1 (1.96) 3.1 (2.2)
Location of home
Urban 23 (25.6%) 23 (31.5%) 53 (18.6%) 79 (25.7%)
Peri-urban 26 (28.9%) 26 (35.6%) 53 (18.6%) 52 (16.9%)
Rural 41 (45.6%) 24 (32.9%) 179 (62.8%) 176 (57.3%)
Place of care
Home 56 (62.2%) 50 (68.5%) 180 (63.2%) 204 (66.4%)
Inpatient 27 (30.0%) 16 (21.9%) 74 (26.0%) 79 (25.7%)
Outpatient 3 (3.3%) 3 (4.1%) 13 (4.6%) 12 (3.9%)
Day care 4 (4.4%) 4 (5.5%) 18 (6.3%) 12 (3.9%)
Weeks under care
Mean (SD) 51.4 (85.2)
a 62.6 (91.2)
a 46.0 (74.8) 39.1 (69.5)
Median 15.0 25.0 12.0 8.0
FAMILY CARERS N 38 29 199 200
Age **
Mean (SD) 44.8 (17.5)
b 46.9 (18.3)
Gender **
Female 32 (84.5%)
b 26 (89.7%)
Household size **
Mean (SD) 7.1 (3.5)
b 6.8 (3.7)
Responsible for
children?
**
Yes 30 (78.9%)
b 24 (82.8%)
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i. Face validity: patients’ and families’ views (Phases 1a and
1b)
Qualitative interviews to map domains of patients
and family concern were conducted with a purposive
sample of patients (N = 90) and family carers (N =
38). Cognitive interviews were carried out with a
subset of these (N = 73 patients, N = 29 carers).
Fewer cognitive interviews than qualitative inter-
views were included in the analysis, as cognitive data
from one of the sites was excluded due to deviation
from the protocol.
Analysis of in-depth qualitative interviews with
patients and carers confirmed that POS items mapped
well onto the main themes of identified need: pain and
symptoms; treatment; psychological well being; reli-
gious belief and spirituality; communication and infor-
mation; family support and carer needs.
Cognitive interviewing demonstrated good interpre-
tation. The item with most frequent problems in
interpretation was question 7: ‘Have you had enough
help and advice for your family to plan for the
future?’ for which 13 interviewees gave responses
indicative of comprehension difficulties.
During the cognitive interviews, when asked if the
POS should include any additional questions. 5 of
t h e s eg a v es u g g e s t i o n sf o ra d d i t i o n s ,4o fw h i c h
related to financial and social support e.g. ‘It h i n ki f
you can ask like “how does a person manage finan-
cially?”‘ (Carer, South Africa)’.
ii. Construct validity (Phase 2)
In Phase 2 of the validation 285 patients completed
the POS and MVQoLI. The Spearman’sr a n kc o r r e -
lations for the POS against MVQoLI items are dis-
played in Table 2. All correlations are low-moderate,
as hypothesized owing to the differences between
the constructs of the two measures. The correlation
analysis of “best fit” domains between the 2 mea-
sures demonstrates that the MVQoLI and APCA
African POS are measuring different elements of
pain/symptoms and spiritual wellbeing.
iii. Internal consistency (Phase 3)
In Phase 3 of the validation, internal consistency was
measured on two data sets from the same sample,
collected during assessment of test/re-test reliability
(N = 307). The a reliability coefficient (Cronbach’s
Alpha) was 0.60 on both data sets. As hypothesized,
this indicates moderate internal consistency.
iv. Test/re-test reliability (Phase 3)
The second visit during test-retest reliability was 3-
48.5 hours after the first (N = 307). The mean time
between visits was 21.2 hours (median 23.2, SD 7.2,
range 3-48.45 hours). 44 (14.3%) patients were vis-
ited for the second time on the same day as the first
visit; 260 (84.7%) were visited the following day, and
2 (0.7%) were visited 2 days later. 1 patient died
between the first and second visits and was
excluded. 107 family carers were unable to respond
to the carer items on both visits and hence were
excluded.
Table 2 Correlations of MVQoLI against the POS
MVQol Item POS Item Correlation coefficient (r)
MVQoLI total POS total* 0.538
MVQoLI total POS total for patient items only* 0.566
MVQoLI symptom subscale Sum (POS Q1* (pain) + Q2* (symptoms)) 0.117
MVQoLI interpersonal subscale POS Q4 (sharing feelings) 0.392
MVQoLI well being subscale Sum POS Q6 (peace) + Q3* (worry) + Q7 (help & advice) 0.435
MVQoLI transcendence subscale POS Q5 (life worthwhile) 0.238
* POS items transformed so that for all items high scores indicated better patient status.
Table 1: Characteristics of validation study participants (Missing N = 0 unless stated) (Continued)
Mean no. of children
(SD)
3.1 (1.6) 3.0 (1.7)
Location of home **
Urban 4 (10.5%) 4 (13.8%)
Peri-urban 10 (26.3%) 10 (34.5%)
Rural 21 (55.3%) 15 (51.7%)
Missing 30
^ Subset of sample 1a
* Carer data not collected for Phase 2 and 3.
a Missing = 1
b Missing = 3
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found for all items, ranging from 0.78 (symptoms) -
0.89 (total POS score) (see Table 3).
v. Time to complete (Phase 3)
The median time to complete the APCA African
POS reduced from 7.00 minutes (mean 9.31, SD
6.69) at the first visit, to 5.00 minutes (mean 7.80,
SD 7.22) at the second visit. In comparison, the
median time to complete for the MVQoLI was 16.00
minutes (mean 19.64, SD 11.76).
Overall levels of missing data were extremely low for
both tools across the sample of 285 individuals.
Where it did occur, it was of an ‘item non-response’
type [25], i.e. single items missing. Given the overall
low levels of missing data, formal statistical methods
to impute missing data were not utilised. Where an
item of the MVQoLI subscale was missing, a score
was not calculated for that subscale and it was
excluded in any analyses (missing data by subscale:
global score, symptom, function and well-being sub-
scales, missing n = 0; interpersonal subscale, missing
n = 2; transcendent subscale missing n = 9). There
were no missing POS scores for items 1-7, which are
the items used in the correlation analyses (missing
data for items 8-10 are reported in Table 3).
Discussion
To date, the evidence base in African palliative care has
been severely limited by the absence of a locally devel-
oped tool for outcome measurement, validated using
robust scientific validation methods [8,9]. This study
met accepted standards for tool validation [26,27].
T h ed a t ap r e s e n t e dh e r ep r o v i d er i g o r o u se v i d e n c e
that the APCA African POS has sound psychometric
properties. The tool also appears to have high levels of
acceptability and utility in the African clinical setting,
which may make it more suitable for use than the
MVQoLI. In particular, Namisango et al do not report
cognitive interview data from the validation of the
MVQoLI in Uganda [13], and the complexity and length
of the tool suggest it may be inappropriate for use in
many settings in Africa. In the Ugandan study the aver-
age time to complete the MVQoLI was between 15 and
35 minutes depending on the performance score [13];
we found a similar mean time of 19 minutes. In con-
trast, the low mean and median time to complete values
for the APCA African POS (mean 8-9 minutes; median
5-7 minutes) indicate that the measure is brief to use
and may be easily incorporated into routine clinical
assessment.
Those affected by life-limiting disease should have the
right to receive evaluated, best quality health care, and
appropriate measures are essential to achieving this goal.
In settings where resources are limited, resource alloca-
tion and provision of care to those with progressive
incurable disease should be guided by locally generated
and relevant evidence.
As with any tool, we recommend that training and
support be provided in its use. This is particularly
necessary when a small number of patients described
comprehension difficulties on a specific item. The
research group is currently developing a manual to pro-
vide guidance on applying the tool in clinical audit.
Since its original development, the Palliative Outcome
Scale has been developed into different cultural/linguis-
tic versions. There is also a trend in outcome measure-
ment toward the use of core and “add-on” scales (for
specific diseases, problems or populations), which may
be appropriate in the African setting as the data pre-
sented suggest that additional items addressing the
socio-economic dimension may be useful.
Application of this tool offers the opportunity to at
last address the omissions of palliative care research in
Sub-Saharan Africa, to generate local evidence using an
Table 3 Intraclass correlation coefficients of scores obtained on first and second visits in test/re-test (patients n = 307)
Item/Total ICC (single measures) Confidence interval (95%) P Excluded
Q1 pain* 0.785 0.737-0.824 0.001 0.3% (N = 1)
Q2 symptoms* 0.775 0.726-0.816 0.001 0.3% (N = 1)
Q3 worry* 0.824 0.784-0.857 0.001 0.3% (N = 1)
Q4 able to share 0.765 0.715-0.808 0.001 0.3% (N = 1)
Q5 life worthwhile 0.812 0.770-0.847 0.001 0.3% (N = 1)
Q6 at peace 0.777 0.728-0.818 0.001 0.3% (N = 1)
Q7 help and advice 0.815 0.773-0.849 0.001 0.3% (N = 1)
Q8 family info 0.882 0.847-0.909 0.001 35.2% (N = 108)
Q9 family confidence 0.831 0.783-0.870 0.001 35.2% (N = 108)
Q10 family worry* 0.857 0.815-0.890 0.001 35.2% (N = 108)
Total POS score* 0.892 0.859-0.917 0.001 35.2% (N = 108)
Total POS patient items only (Q1-Q7)* 0.876 0.847-0.899 0.001 0.3% (N = 1)
* POS items transformed so that for all items high scores indicated better patient status.
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measure into routine clinical audit. The APCA African
POS has now been adopted in a number of clinical
audit and longitudinal research studies across Africa.
Conclusions
Despite the strengths of a multi-centre, international
approach with early and ongoing input of pan-African
clinicians and researchers, and the full validation in
diverse inpatient and home care settings, in both HIV
and cancer diagnoses, across disease stages and ART
use, there are several limitations to our study. Firstly, we
have only been able to develop and validate a tool for
use in adult populations. We believe that a tool for pae-
diatric palliative use is urgently needed for Africa. Sec-
ondly, the translation into many languages is necessary
for Africa, and while we have followed best practice, we
accept that cultural difference in meaning may poten-
tially lead to different understandings. We have
attempted to investigate this through the cognitive inter-
views. We believe that the value of cognitive interviews
in tool validation is that, while all potential comprehen-
sion/understanding differences can never be designed
out of a tool for wide application, awareness can be
applied in training and application. Third, while a ver-
sion of the MVQoLI has been validated among
advanced AIDS patients in Uganda [28], the small num-
ber of changes in the newer version and the populations
studied in our validation (i.e. different stages of both
HIV and cancer across South Africa and Uganda) led us
to choose the original version. The lack of a previously
validated tool in these populations limited our choices
of a comparator. As the MVQoLI was not designed for
patients with life limiting illness from the point of diag-
nosis to the end of life (i.e. the full range of potential
palliative care intervention) we plan to investigate how
it behaves according to disease stage.
The APCA African POS is currently in use in a num-
ber of clinical trials and longitudinal studies across a
range of diseases and countries. We believe that use of
this tool may significantly advance the measurement,
and improvement, of care for African patients and
families affected by life-limiting incurable disease.
Additional file 1: The APCA African POS. The full and final validated
tool.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-7525-8-10-
S1.DOC]
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